-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...

-The Indian Express The World Universal Health Coverage Day, observed on December 12, builds on growing global momentum towards introducing universal health coverage (UHC) in national health plans and reinforces the case for including UHC as a prominent sustainable development goal to be adopted by the UN next year. India proposes to implement a programme of national health assurance, which embraces the principles of UHC. It is expected that the government...

-Business Standard This would be in addition to 348 drugs already under price ceiling The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of another 52 essential drugs, in a move that could impact drug manufacturers Lupin, Cadila Healthcare and Merck. This is in addition to the 348 drugs already under a price ceiling. The majority of the 52 new drugs are antibiotics, painkillers and medicines used for treating cancer and skin...

-The Times of India NEW DELHI: The government's price control measure for essential medicines has had an unexpected fallout - several of these drugs, including those for treatment of chronic ailments such as high uric acid levels, diabetes and acne, are either in short supply or have gone missing from chemist shops. Among the drugs facing shortage are Zyloric (prescribed for uric acid control), Ocid (acidity), CCM (calcium supplement) and Etroxin (a...

-Business Standard Domestic regulators need to be stricter about quality violations to protect both Indian pharma exports as well as the country's image Even as major Indian drug companies continue to make news for impurities in the medicines they make and faulty - or if the USFDA is to be believed, falsified - data that many generate after testing of samples show quality problem, it seems strange that domestic authorities are silent...